Aduhelm sparks controversy as a therapy drug for Alzheimer’s patients that attacks amyloid plaques in the brain, and slows the decline of memory and problem-solving by about 25% over time. It’s not a cure, and it can’t even restore lost mental capabilities. Now that the FDA has fast-tracked approval, should American taxpayers cover the $56,000/year per patient cost for relative minor results?
Scott Ott, Stephen Green and Bill Whittle create 240 new episodes of Right Angle annually, thanks to our Members. Join us now.
Video below hosted at Rumble.